PALO ALTO, Calif.--(BUSINESS WIRE)--Aragon Surgical, Inc., a venture backed emerging medical device company, announced today that it has received FDA clearance for the IntelliSeal OS12, the first instrument in their platform of RF products that will cross a broad array of specialties. The OS12 was designed with gynecologists for use in abdominal (“open”) hysterectomy.
“We are very excited about introducing this unique surgical device to gynecologists,” said Roseanne Varner, President and CEO of Aragon Surgical. “Feedback from both physician users and potential users on the obvious advantages of this device has been very positive.”
The IntelliSeal™ product line utilizes proprietary TissueSense™ technology in all of their electrosurgical instruments and systems. This unique energy delivery platform serves as the foundation for several open and laparoscopic surgical instruments. All IntelliSeal electrosurgical systems are designed to reduce operative time and improve patient safety.
Aragon Surgical plans to introduce additional products that utilize their proprietary TissueSense™ technology in 2009.
About Aragon Surgical, Inc.
Located in Palo Alto, California, Aragon Surgical is a venture backed, market driven surgical device company that is developing and commercializing a variety of surgical instruments intended to reduce operative time and improve patient safety, benefiting both patients and surgeons. Aragon Surgical was founded in 2005 and is funded by Bay City Capital, Delphi Ventures, ONSET Ventures and Integral Capital Partners.
Aragon Surgical, Inc.
Christine L. Cunningham, 650-543-3100
Vice President of Marketing & Business Development
Source: Aragon Surgical, Inc.